Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
UCB |
---|---|
Information provided by: | UCB |
ClinicalTrials.gov Identifier: | NCT00139867 |
The objective of this trial was to assess subject preference for PARCOPA, carbidopa/levodopa Orally Disintegrating Tablets (ODT), compared with conventional carbidopa/levodopa tablets, in subjects with stable Parkinson's disease.
Condition | Intervention | Phase |
---|---|---|
Parkinson's Disease |
Drug: PARCOPA |
Phase III |
Study Type: | Interventional |
Study Design: | Randomized, Open Label, Dose Comparison, Crossover Assignment |
Official Title: | A Multicenter, Open-Label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | SP780 |
Study First Received: | August 29, 2005 |
Last Updated: | April 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00139867 |
Health Authority: | United States: Institutional Review Board |
Levodopa Dopamine Ganglion Cysts Movement Disorders Parkinson Disease Sinemet |
Carbidopa Basal Ganglia Diseases Central Nervous System Diseases Parkinsonian Disorders Neurodegenerative Diseases Brain Diseases |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Immunologic Factors Anti-Dyskinesia Agents Nervous System Diseases Physiological Effects of Drugs Adjuvants, Immunologic |
Antiparkinson Agents Enzyme Inhibitors Dopamine Agonists Pharmacologic Actions Therapeutic Uses Dopamine Agents Central Nervous System Agents |